From First-in-Human to Proof-of-Concept – Expert Early Phase Trial Solutions
GCP ClinPlus provides comprehensive clinical phases of drug development services in China, offering global biopharma and biotech companies a reliable and cost-effective pathway for first-in-human and proof-of-concept studies. With over 22 years of experience, over 2,200 projects completed, and 210+ product approvals, we are trusted by clients worldwide for our speed, scientific rigor, and data quality. Our expertise spans multiple therapeutic areas, including oncology, cell and gene therapy, and rare diseases. Backed by deep regulatory knowledge and strong partnerships with NMPA-accredited early-phase units, we help sponsors generate high-quality data that meets FDA, EMA, and NMPA standards—accelerating global development.
Your Gateway to Global Development – Integrated Early Phase Trial Services
Early-phase clinical trials are pivotal in shaping the success of any drug development program. These studies help establish safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and initial efficacy signals—serving as a foundation for future phases. Conducting early-phase studies in China offers international sponsors strategic benefits, including access to a large patient population, efficient timelines, and significant cost savings.
We work closely with top-rated early-phase clinical pharmacology units across China, many of which offer green channel capabilities for faster study start-up. Our end-to-end support includes:
Pre-IND consulting and study design
Regulatory strategy and NMPA submissions
Site identification, contract negotiation, and activation
Medical monitoring, PV, and data safety oversight
Full-service biometrics including data management, biostatistics, and programming
Our teams include former FDA reviewers, PhD-level statisticians, and CGT experts who ensure global regulatory compliance and data credibility. For companies exploring novel modalities—including biologics, RNA-based therapeutics, and cell/gene therapies—our scientific leadership and operational flexibility provide added value.
Whether you aim to generate first-in-human data, conduct PK bridging for global submission, or assess proof-of-concept in Chinese populations, GCP ClinPlus offers a trusted, streamlined, and science-driven solution.
Why Global Sponsors Choose GCP ClinPlus for Early-Phase Studies in China
Global-Standard Compliance: FDA/EMA/NMPA-aligned data and processes.
Cost-Effective: Up to 50–80% savings vs. U.S./EU trials.
Faster Start-Up: 30% shorter timelines via green channel and strong SSU team.
Strategic Insight: Regulatory, clinical, and scientific expertise under one roof.
Scientific Credibility: Trusted by leading biotechs for first-in-class therapies.
Robust Site Network: Access to China's top early-phase units and hospitals.
End-to-End Support: From pre-IND to study close-out with full project ownership.
Client-Centered: Agile, responsive, and dedicated to your trial’s success.
Testimonials of GCP ClinPlus
Head of Biometrics, Leading Biotech
"
GCP ClinPlus delivers exceptional expertise with genuine commitment to our projects. Their team demonstrates remarkable responsibility at every stage, consistently going above and beyond. In an industry where dedication matters, they've proven themselves an invaluable partner for our success.
"
VP of Clinical Development, Biotech
"
After enrollment challenges with our previous China HV CRO threatened our study timeline, GCP ClinPlus stepped in and transformed our project. Their team rapidly accelerated patient recruitment beyond our expectations and put our critical study back on track. Their clinical expertise and swift implementation proved decisive in securing our study's success.
"
Project Manager, Pharmaceutical Company
"
GCP ClinPlus stands out for their exceptional responsiveness and customer focus. Their team consistently prioritizes our needs with prompt, thoughtful solutions to every challenge. Their combination of technical excellence and client-centered approach makes them a truly strategic partner in our development programs.
"
Therapeutic Areas
Delivery Model
They have proven to be an outstanding FIH CRO in China. Their in - depth understanding of the Chinese regulatory environment and local clinical trial landscape gives them a significant edge. They are well - versed in the unique requirements of First - in - Human (FIH) trials in China, ensuring smooth and compliant operations.
Their capabilities in patient recruitment are remarkable. They have a wide network and effective strategies to quickly identify and enroll suitable participants for FIH trials. This not only shortens the trial timeline but also enhances the quality of data collection.
Moreover, their data management and analysis for FIH trials are top - notch. They use advanced technologies and experienced personnel to handle the complex data generated during these early - stage trials. This allows for accurate and timely insights, which are crucial for making informed decisions in the development process.
In addition, they maintain high - level communication throughout the FIH trial process. They keep all stakeholders, including sponsors and regulatory authorities, well - informed about the progress and any emerging issues. Their proactive approach in addressing challenges and providing solutions has earned them a reputation as a reliable China FIH CRO.
If you want to know more about China FIH trial and China HV study, please visit our website.
At GCP ClinPlus, we deliver end-to-end clinical research solutions—from early-phase development, pivotal studies to post-marketing support—designed to accelerate timelines, improve efficiency, and reduce costs. Our integrated services include statistical support, regulatory consulting, and comprehensive clinical operations for innovative drugs, advanced therapies, medical devices, and a broad range of therapeutic areas. With seamless collaboration across operational and functional teams, we ensure your projects move forward efficiently and successfully.
